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Background: Medical apps are widely available, increasingly used by patients and clinicians, and are being actively
promoted for use in routine care. However, there is little systematic evidence exploring possible risks associated
with apps intended for patient use. Because self-medication errors are a recognized source of avoidable harm, apps
that affect medication use, such as dose calculators, deserve particular scrutiny. We explored the accuracy and clinical
suitability of apps for calculating medication doses, focusing on insulin calculators for patients with diabetes as a
representative use for a prevalent long-term condition.
Methods: We performed a systematic assessment of all English-language rapid/short-acting insulin dose calculators
available for iOS and Android.
Results: Searches identified 46 calculators that performed simple mathematical operations using planned carbohydrate
intake and measured blood glucose. While 59% (n = 27/46) of apps included a clinical disclaimer, only 30% (n = 14/46)
documented the calculation formula. 91% (n = 42/46) lacked numeric input validation, 59% (n = 27/46) allowed
calculation when one or more values were missing, 48% (n = 22/46) used ambiguous terminology, 9% (n = 4/46)
did not use adequate numeric precision and 4% (n = 2/46) did not store parameters faithfully. 67% (n = 31/46) of
apps carried a risk of inappropriate output dose recommendation that either violated basic clinical assumptions
(48%, n = 22/46) or did not match a stated formula (14%, n = 3/21) or correctly update in response to changing
user inputs (37%, n = 17/46). Only one app, for iOS, was issue-free according to our criteria. No significant differences
were observed in issue prevalence by payment model or platform.
Conclusions: The majority of insulin dose calculator apps provide no protection against, and may actively contribute
to, incorrect or inappropriate dose recommendations that put current users at risk of both catastrophic overdose and
more subtle harms resulting from suboptimal glucose control. Healthcare professionals should exercise substantial
caution in recommending unregulated dose calculators to patients and address app safety as part of self-management
education. The prevalence of errors attributable to incorrect interpretation of medical principles underlines the
importance of clinical input during app design. Systemic issues affecting the safety and suitability of higher-risk
apps may require coordinated surveillance and action at national and international levels involving regulators,
health agencies and app stores.
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The rise of apps, software programs that run on devices
like smartphones, creates novel opportunities for health-
care and disease management. Consumer surveys suggest
that three-fifths of US adults [1], and over 1.5 billion
worldwide [2], own an app-capable smartphone. App* Correspondence: c.huckvale@imperial.ac.uk
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or free information apps, diaries, and other tools intended
to help individuals manage their health and share data
with professionals [3]. Utility functions, such as drug dose
calculators, that can be integrated into daily routines have
become a common feature in medical apps [3]. While a
quarter of adults report already using a health or fitness-
tracking app [4], nine out of ten state that they would be
happy to receive a mobile app “on prescription” from aal. This is an Open Access article distributed under the terms of the Creative
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ommended an app to a patient in the past year [6]. Apps
are now a routine feature of health policy discussions
[7-9] and government strategy [10]. While recognizing
potential benefits for care experience, outcomes, and re-
source utilization, recent discussion has identified gaps in
evidence concerning effectiveness and safety [11-14].
Medical apps that are poorly designed, or do not function
as intended, pose a potential risk to patients and threaten
confidence among clinicians, patients, and the broader pub-
lic. There is a spectrum of risk. Apps that support educa-
tion and disease tracking may not adhere to evidence-based
practices [15-17], but are unlikely to be actively harmful. In
contrast, problems in apps with diagnostic and therapeutic
functions, including calculators intended to recommend a
dose of medication, may directly affect health outcomes.
Poor diagnostic sensitivity has been identified in apps offer-
ing diagnostic screening for skin cancer [18], raising the
possibility of missed or delayed diagnosis. Errors have been
found in calculator apps intended to establish treatment
thresholds for asthma [19] with potential consequences
ranging from unnecessary treatment to unplanned care
use resulting from the failure to recognize early signs of
deterioration. Medication-related functions deserve par-
ticular scrutiny. Adverse drug events resulting from pre-
scriber and patient errors are a common cause of avoidable
harm in hospital and ambulatory care [20-23]. Up to one
in seven patients report having experienced a medication
error in the past two years [24]. The potential for new risks
arising from the use of medication apps is suggested by the
withdrawals of a small number of products, including
an insulin dose calculator developed by a pharmaceutical
company, because of clinically relevant errors [8,25]. While
calculator apps designed for use by healthcare professionals
have been subject to scrutiny [26], the safety characteristics
of those intended for patient use are largely unknown.
This study aimed to systematically explore the clinical
suitability of app-based dose calculators intended for pa-
tient use, using the example of diabetes mellitus as a long-
term condition that is routinely encountered in ambulatory
and hospital care. Many patients with diabetes need to
adjust long-acting therapy with a series of tailored insulin
doses taken throughout each day before meals and snacks,
or to correct high blood sugar levels. Individuals must
calculate a dose that correctly integrates expected carbo-
hydrate intake, measured blood glucose levels, and past
insulin doses [27]. To assist with this process, dedicated
dose calculators are already available, both as dedicated
physical devices and integrated into pumps and meters.
Apps offer a novel platform for calculation that is avail-
able wherever a patient takes his or her smartphone.
We undertook a systematic assessment of the design and
behavior of English-language rapid-acting insulin calculators.
We attempted to provide an exhaustive characterization ofissues that might affect their suitability for use in clin-
ical practice.
Methods
The study used a cross-sectional design which attempted
to review all apps available at a particular point in time.
We adapted principles from systematic literature review
to structure a process of app identification and evaluation
that aimed to minimize bias and error during assessment.
App selection
The UK versions of online app marketplaces for the two
most widely used smartphone operating systems were
searched in August 2013 using a predefined strategy (detailed
in Additional file 1: Methods AF1). Obviously irrelevant apps
were eliminated by reviewing app store descriptions and
screenshots to identify apps that were either unrelated to dia-
betes self-management or for which no calculator could be
present, for example, diabetes eBooks. The remaining apps
were downloaded and evaluated using prespecified inclusion
and exclusion criteria. Each stage of search and selection was
performed by at least two investigators (of KH, SA, and JTP),
working independently. Consensus was reached by pooling
independent decisions and resolving any discrepancies
through group discussion involving all search investiga-
tors in which discrepant apps were re-reviewed against
selection criteria. We planned to involve an independ-
ent arbiter (JC) in the event that resolution was not
possible, but in practice this was not needed.
Apps were eligible for inclusion if they were in the English
language and contained a tool for performing a mathemat-
ical operation on one or more patient- and context-specific
numeric parameters to suggest a dose of rapid or short-
acting insulin. We applied the following inclusion and
exclusion criteria:
Inclusion criteria
 Smartphone or tablet app
 Containing a rapid-acting insulin dose calculator, a
tool to perform a mathematical operation on one or
more patient- and context-specific numeric parameters
 English language
 Targeted at patients of any age or clinicians, or both
(in practice, all the apps included in this study
targeted patients)
 Free and paid apps
Exclusion criteria
 Not available through Android or iOS device
marketplaces
 Could not be downloaded because of country
restrictions that prevented access in the United
Kingdom
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after two attempts
 Sliding scales, lookup tables or other standard
instruments that do not involve mathematical
transformation of patient-supplied inputs
Apps were not restricted by cost, country of origin,
target platform, download count, or intended audience.
Consistent with the approach taken by medical regulators
[28], calculators explicitly disclaiming medical use for self-
management or treatment were not excluded, since the
only valid use of a product advertised as a drug dose
calculator is for medical purposes. Apps meeting the in-
clusion criteria were excluded only if technical issues
prevented them from being downloaded or run on test
devices. Duplicate apps running on the same platform
were excluded. However, apps available on both iOS and
Android were retained to assess consistency between the
operating systems. App stores were rechecked in October
2014 to see if included apps remained available for down-
load or had been updated during the study period. Up-
dated apps were reevaluated.Assessment procedures
Apps were assessed using a standardized method to exam-
ine each component of the calculation process (Additional
file 1: Methods AF2). Expected inputs and outputs, sup-
ported unit systems, terminology, and any supplementary
app features were characterized by inspection. Simulated
data were used to define behavior in response to missing
and extreme input values. Where the formula used for
calculation was not displayed in the app or in associated
documentation, the developer was contacted. For those
apps where a formula was ultimately identified, perform-
ance was assessed using a set of test cases generated by
permutation of the range of possible values for each in-
put parameter (further described in Additional file 1:
Methods AF3). Where present, clinical disclaimer text
was extracted and coded to identify statements advocat-
ing discussion with a healthcare professional prior to
calculator use and the role of personal judgment in inter-
preting generated results. All apps were assessed by a
clinician-researcher (KH) and a second reviewer (either
JTP, a mobile health researcher, or SA, a public health re-
searcher), working independently. While also intended to
minimize the risk of bias, comparison of these independ-
ent reviews served mainly to identify accidental errors or
omissions during assessment. We planned for a third
investigator to provide arbitration in the event that dif-
ferences could not be resolved by discussion, but in
practice this was not required, and the small number of
scoring differences were resolved by rechecking the af-
fected apps.Statistical analysis
Issues identified within apps were aggregated for analysis.
The schema used for grouping (Table 1) was informed by
previous work [19,29] and refined through discussion and
divided issues into two broad categories depending on
whether they concerned the process of data entry (input
issues) or the results that were generated (output issues,
Table 1). This partitioning accounted for both the differing
potential for error, in our view, and the availability of
potentially mitigating strategies. Thus, while input issues
tended only to increase the likelihood of an incorrect
value being used for calculation, output issues were con-
cerned with errors arising despite no error on the part of a
user. Operational criteria for this schema are provided in
Additional file 1: Methods AF4. Simple descriptive sta-
tistics were used to summarize the prevalence of issues
within the schema.
Before starting analysis, we hypothesized that the preva-
lence of identified issues might vary both by platform and
the payment model (free or paid), because apps for iOS
are subject to a quality control process prior to release
whereas Android has no such requirement, and because
developers of paid-for apps may invest more in quality
assurance. Fisher’s exact test was used to calculate the
two-tailed probability of an association between issue
prevalence and platform or distribution model. A signifi-
cance level of 0.05 was prespecified. Statistics were com-
puted with R (Version 3.0.0) using the package exact2x2
(Version 1.4.0).
Results
Forty-six apps (21 Android, 25 iOS) were selected for in-
clusion into the study (Figure 1). Of these, nine were
available on both platforms but evaluated separately.
Details of excluded apps are provided in Additional file 2:
Table AF5.
Approximately two-fifths (37%, n = 17/46) of apps were
standalone calculators (Table 2, detailed in Additional
file 2: Table AF6). Most (59%, n = 27/46), however, com-
bined a calculator with a diary for recording blood glucose
measurements. Over half of apps (59%, n = 27/46) in-
cluded a clinical disclaimer. Most disclaimers emphasized
the importance of discussing use of a calculator with a
physician (n = 12/27) and using judgment before accepting
any dose recommendation (n = 10/27). A small number
(n = 4/27) explicitly stated that the app should not be used
for treatment or other medical purposes. However, be-
cause these apps were clearly advertised as dose calculators
they were retained for analysis. One iOS app was associ-
ated with an evidence-based diabetes self-management
education program [30,31] and another, available for both
iOS and Android, had been developed by healthcare pro-
fessionals [32]. Download counts were available for An-
droid, but not iOS. While not necessarily reflecting the
















Input issues 44 (96%) 21 (100%) 23 (92%) 0.493 20 (95%) 24 (96%) 1.000
Numeric validation
lacking
Inputs unconstrained by physiologically
or logically plausible limits, for example,
negative values accepted.
42 (91%) 21 (100%) 21 (84%) 20 (95%) 22 (88%)
No validation of any
input
For example, textual values allowed in
all numeric fields.
24 (52%) 14 (67%) 10 (40%) 12 (57%) 12 (48%)
Some validation Inconsistency reflecting use of validation
for only some inputs.
18 (39%) 7 (33%) 11 (44%) 8 (38%) 10 (40%)
Calculation despite
missing inputs
For example, correction bolus calculated
even though insulin to blood glucose
ratio not provided.
27 (59%) 14 (67%) 13 (52%) 10 (48%) 17 (68%)
Ambiguous terminology Use of ambiguous labeling or descriptions
creates risk of misinterpretation.
22 (48%) 8 (38%) 14 (56%) 8 (38%) 14 (56%)
Data entry issues User data cannot be entered faithfully or
are not stored correctly for calculation.
6 (13%) 3 (14%) 3 (12%) 4 (19%) 2 (8%)
Precision issues For example, a data field for measurements
in mmol/L that accepts only whole integers.
4 (9%) 1 (4%) 3 (14%) 4 (19%) 0 (0%)
Data not stored correctly Data change unexpectedly, for example,
transposed into a different data field.
2 (4%) 2 (8%) 0 (0%) 0 (0%) 2 (8%)
Output issues 31 (67%) 17 (81%) 14 (56%) 0.115 14 (67%) 17 (68%) 1.000
Clinical model violation Calculation does not conform to principles
of underlying clinical conceptual model,
for example, by assuming an omitted
blood glucose implies a measured value
of zero.
22 (48%) 13 (62%) 9 (36%) 10 (48%) 12 (48%)
Formula inconsistency † Calculation does not proceed in accordance
with the stated formula.
3 (14%) 1 (11%) 2 (17%) 0 (0%) 3 (23%)
Input–output mismatch Calculator output is not consistently
synchronized with changing user inputs.
17 (37%) 9 (43%) 8 (32%) 8 (38%) 9 (36%)
Automatic calculator A calculator which normally refreshes
output automatically in response to
changing inputs does not under certain
circumstances.
3 (7%) 2 (10%) 1 (4%) 0 (0%) 3 (12%)
Manual calculator App does not respond reliably to manual
commands to recalculate dose, for example,
tapping a “Calculate” button.
14 (30%) 7 (33%) 7 (28%) 8 (38%) 6 (24%)
Other software errors Software unexpectedly crashes or becomes
unresponsive during normal use.
11 (24%) 8 (38%) 3 (12%) - 4 (19%) 7 (28%) -
*Two-tailed P value for the comparisons between Android and iOS and Free and Paid apps respectively, calculated using Fisher’s exact test.
† The denominator used for calculating percentages for this issue was the number of apps for which a formula was identified (n = 21, Android 9, iOS 12, Free 8,
Paid 13).
Input issues affect the entry of data and increase the risk that calculation will proceed without correct parameters. Output issues affect interpretation of the
calculated value. They create a risk of incorrect dose recommendation even when all input parameters have been supplied correctly. While input issues may be
amenable to corrective action taken by a user, for example, by double-checking data entry, output issues may only be effectively addressed through changes to
the software.
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gate estimate of at least 105,000 global downloads of
the calculators included in the study by October 2014.
While the majority of Android calculators had relatively
low download counts (median 1000), three apps had
been downloaded at least 20,000 times each.
All apps performed a basic meal bolus calculation, de-
signed to work out the amount of insulin required tooffset counted carbohydrate intake that was extended in
most cases (83%, n = 38/46) with an adjustment for
current blood glucose measurements (Additional file 2:
Table AF7). All apps accepted inputs entered manually
by the user. Eight apps provided a food database for quan-
tifying carbohydrate intake. One (Glucose Meter for
Android [33]) supported automatic transfer of blood
glucose measurements from a Bluetooth-enabled meter.
Table 2 Characteristics of included dose calculator apps
Number by platform (%)
Android (n = 21) iOS (n = 25)
App type
Standalone calculator 6 (29%) 11 (44%)
Diary with integrated calculator 14 (67%) 13 (52%)
Other* 1 (5%) 1 (4%)
Region of origin
Europe 11 (52%) 12 (48%)
North America 6 (29%) 8 (32%)
Asia and Australasia 4 (19%) 5 (20%)
Cost
Free 9 (43%) 10 (40%)
Paid for 12 (57%) 15 (60%)
Releases
Updated during study period 5 (24%) 12 (48%)
Updated in 12 months prior 13 (62%) 16 (64%)
Still available at close of study 20 (95%) 22 (88%)
Self-management features
Food database 3 (14%) 5 (20%)
Data sharing 11 (52%) 8 (32%)
Reminders 3 (14%) 3 (12%)
Other features
Clinical disclaimer 11 (52%) 16 (64%)
Accreditation 1 (5%) 2 (7%)
In-app help 12 (57%) 13 (52%)
Support contact 10 (48%) 16 (64%)
*One app available for both Android and iOS contained information about
insulin pump therapy but included a dose calculator as an additional feature.
Many pumps themselves contain dose calculators, potentially rendering a
separate calculator redundant.
Figure 1 App selection process.
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additional adjustments for exercise levels (n = 10), mea-
sured ketones (n = 2), and lipids (n = 1). Two-fifths of
apps (39%, n = 18/46) allowed calculations to be tailored
by specific events (for example, mealtimes, n = 12), time of
day (n = 6), or both (n = 1). No apps performed adjust-
ments for basal insulin regimes or, for type 2 diabetic
patients, combined oral and injected therapy.
The formula used to suggest an insulin dose was listed
in a third (n = 14/46) of apps and obtained on request
for a further seven. Just under half (46%, n = 21/46) of
developers did not respond to requests for information,
contact details were not found for two, and two refused
on grounds of commercial confidence. Formulae were
broadly consistent across apps. Meal boluses were gener-
ated by dividing carbohydrate intake by a user-supplied,
personal carbohydrate factor; the number of grams of
carbohydrate required to offset the reduction in blood
glucose caused by one unit of rapid-acting insulin. Cor-
rection boluses were derived similarly, by dividing the
difference between current and target blood glucose
values by an insulin sensitivity factor; the expected re-
duction in blood glucose in response to 1 unit of insulin
for an individual. Some apps used the inverse form of
carbohydrate (n = 9) and insulin sensitivity (n = 2) factors,
performing a multiplication operation to calculate meal
and correction boluses instead. Postprandial adjustments
of correction boluses were supported in a fifth (22%, n =
10/46) of apps that either attempted to model residual
insulin activity (n = 5) or supported post-meal custom
factors (n = 5). One app provided a warning that two-
hour postprandial corrections should be adjusted to reflect
the pharmacokinetics of a recent mealtime dose. Most
(76%, n = 35/46), however, relied on the user to know that
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avoid a risk of overdose.
Input issues
All Android apps (n = 21) and most (92%, n = 23/25) iOS
apps had issues affecting data input that might increase
the risk of an incorrect value being used for calculation
(Table 1). The majority (n = 21/21 and n = 21/25 of An-
droid and iOS apps, respectively) did not apply valid-
ation to all numeric inputs. Measured blood glucose
was the most likely to have some form of validation.
24% (n = 11/46) of apps either flagged extreme values with
a written message (n = 7) or using color (n = 4), but only
one refused to complete calculation. Two-fifths (40%, n =
10/25) of iOS and two-thirds (67%, n = 14/21) of Android
apps placed no range limits on any input. A small number
of apps (n = 1 and n = 4 of Android and iOS, respectively)
allowed textual input in numeric fields. Four apps for iOS
applied validation to all numeric inputs. Three-fifths (59%,
n = 27/46) of all apps allowed calculation to proceed when
one or more values was missing. A small number of apps
had data entry issues, such as mmol/L glucose measure-
ments constrained to be whole integer values, that meant
that data were either not preserved correctly (n = 2) or
could not be entered with appropriate precision (n = 4).
Just under half (48%, n = 22/46) of apps used ambiguous
terminology to label and describe inputs. Non-specific terms
like “correction factor” were common but used inconsist-
ently, describing both insulin sensitivity and carbohydrate
factors in different apps. In addition, there appeared to be a
geographical basis for certain calculation conventions. Apps
originating from the USA (n = 13) expected meal boluses to
be calculated using a carbohydrate factor, while most apps
from Germany (n = 5/6) required the inverse form of the
factor. Poor documentation meant that the expected form
would be invisible to users in half (50%, n = 23/46) of apps.
In a small number of cases (n = 3), labeling was frankly in-
correct. For example, one app used the phrase “Insulin units
to decrease blood glucose by 1 mmol/L” to describe insulin
sensitivity factor.
Output issues
When no missing or out-of-range input values were
present, the majority of apps with a known formula (86%,
n = 18/21) calculated a result consistent with expectations
during systematic testing. Only three apps deviated from
their stated formulae. Two introduced an undocumented
conversion of glucose values expressed in mmol/L into
mg/d, an unnecessary step because a patient using SI base
units for glucose would almost certainly not have adjust-
ment factors expressed using conventional US units. A
third app silently discounted any negative correction
bolus, contradicting the stated formula and creating a
risk of over-estimating insulin requirements.Formula concordance did not guarantee, however, that
apps would produce correct output under all circumstances.
Over two-thirds (67%, n = 31/46) of all apps, including 19 of
those with known formulae, carried the risk of displaying an
incorrect or inappropriate result despite inputs being config-
ured correctly. Two apps set limits on the maximum insulin
dose that would be prescribed, and two used coloring to
highlight doses exceeding 20 units, but most apps placed no
limits on the calculated insulin dose. Three-fifths (62%, n =
13/21) of Android and two-fifths (36%, n = 9/25) of iOS apps
violated basic clinical assumptions, for example, treating a
missing glucose measurement as a real valued number of
zero for calculation (n = 13) or failing to reduce a recom-
mended meal bolus when blood glucose was below target
values (n = 6). Of the 27 apps that performed calculation
automatically whenever inputs were changed, three did not
always update their output in response to changing inputs.
Three-quarters (74%, n = 14/19) of the remaining apps that
required a manual button press to perform calculation did
not clear the calculated output when inputs were changed.
Challenging our hypotheses, there was no significant
difference in the frequency of input or output issues
grouped either by platform type or distribution model,
although there was a tendency towards a greater propor-
tion of output issues, and clinical model violations in par-
ticular, in apps for Android. Only one app, for iOS, was
issue-free according to our criteria. A second iOS app had
no identified issues, but did not complete systematic out-
put testing because the developer did not respond to re-
quests for details of the formula. If input validation issues
were ignored, a further five apps were otherwise issue-
free. While comparison of each of the nine app pairs avail-
able on both iOS and Android found no differences in
expected inputs, formulae, and outputs, inconsistencies
were found during quality assessment. In four cases,
Android apps performed no numeric validation, while
the iOS version either validated some (n = 3) or all (n = 1)
fields. In two cases, the iOS version accepted textual values
where the Android version did not. In one case, an An-
droid app lacked explanatory text present in the iOS ver-
sion that prevented misinterpretation of an ambiguously
labeled input. A further two Android apps either displayed
incorrect behavior when handling missing values (n = 1)
or did not permit data entry with appropriate precision
(n = 1). At the conclusion of the nine-month review
process, 89% (n = 41/46) remained available in app stores.
18 (44%) had been updated, and one known issue (a data
entry bug involving values being stored incorrectly) was
resolved.
Discussion
Sustained glycemic control is associated with better out-
comes in diabetes [34,35]. Improved control has been
observed in patients receiving continuous subcutaneous
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tor [36,37]. App-based calculators offer a potential alterna-
tive for patients using insulin therapy. They may enhance
the accuracy of insulin dosing, for example, by helping
to precisely quantify carbohydrate intake. By eliminating
mental arithmetic, they may reduce the perceived burden
of calculation, particularly for those with limited func-
tional numeracy. In addition, a smartphone, an object not
typically associated with medical care, may offer a discrete
way to determine dosage in social situations like meal-
times. There is certainly interest from patients. At least
105,000 patients worldwide downloaded apps included in
this study. Historically these are likely to be patients with
type 1 diabetes, for whom insulin therapy is a mainstay.
The growing emphasis on tight control in the much larger
population of type 2 diabetic patients means that insulin
therapy, and the potential user base for calculator apps, is
likely to increase in the future.
Appropriately designed apps may also protect against
calculation errors. Insulin has a narrow therapeutic range
[23], and the incidence of unintentional overdoses relating
to medication errors made by patients is increasing as
intensive therapy becomes commonplace [38]. While
the consequences of insulin overdose are rarely fatal [39],
hypoglycemic events are unpleasant and medication-
related problems contribute to unscheduled care use by
people with diabetes [40]. Our findings show that it is
possible to design dose calculation apps that validate
user input, generate correct output, apply appropriate
dose ceilings, and flag potentially unsafe conditions. How-
ever, these apps are in the minority. A lack of standard
terminology and simple numeric validation provide latent
conditions that increase the risk of unintentional data
entry slips and mistakes related to misunderstanding in
most apps [41]. While these “input” issues are potentially
amenable to intervention, for example, by educating indi-
viduals to double-check the data that they enter in an app,
we also identified a large number of “output” issues, which
reflect fundamental problems in the underlying soft-
ware that cannot easily be mitigated by users. In par-
ticular, two-thirds of included apps carried the risk of
inappropriately large outputs being generated when in-
puts had been specified correctly, including those that
would almost certainly result in hypoglycemia. Many
apps displayed behaviors that suggested that developers
did not fully understand the clinical basis for calculation.
For example, there is no situation where it is clinically ap-
propriate to treat an absent blood glucose value as though
it is a measured value of zero. Agreement with a docu-
mented formula (when available) is an encouraging
finding, and one consistent with recent work examin-
ing calculator apps for clinicians [26]. However, appro-
priate insulin dose recommendations must also take
into account contextual and behavioral factors. This isparticularly important in calculators intended for pa-
tients, who may not have sufficient clinical knowledge
to be able to reject incorrect doses. Yet over three-
quarters of apps did not offer a mechanism for reducing
postprandial boluses to reflect residual insulin activity,
and one in six did not reduce dose recommendations
in response to hypoglycemia. Apps relied exclusively
on users to adjust calculation parameters to reflect
basal insulin and oral antidiabetic regimes and other
factors that might adjust insulin response, like pregnancy.
Detecting potential issues within apps may be challen-
ging. Some issues were only apparent after exhaustive test-
ing. The reasons that might prompt use of a calculator
might also make it hard for patients to detect errors
during use. Patients with limited numeracy may lack an
intuitive basis with which to “sense check” unusual results
[42]. The social contexts in which a calculator might be
used, such as mealtimes, may mean people attend less to
the process of calculation and scrutinizing of the output.
App disclaimers frequently encouraged patients to review
the calculated dose, but over two-thirds failed to provide
details about the underlying formula that would enable
this, and only a small number of apps flagged unusual in-
put or output values. One potentially attractive strategy is
to equip individuals with skills to recognize inappropriate
or potentially harmful app during their initial search.
Simple criterion-based approaches have been used to
help consumers judge the quality of websites [43], and
criteria have recently been proposed for apps that either
rely on structured disclosures by developers addressing a
number of generic quality domains [44], such as testing
undertaken during development, or incorporate proxies
for quality, such as disclosure of authorship [45]. Struc-
tured reporting has the potential to flag issues that make
calculators unsuitable for particular user groups, for ex-
ample, unit systems incompatible with local practices.
However, at present, no calculator-specific instruments
exist, while content-independent instruments rely on de-
velopers to appreciate that these are relevant concerns in
the first place. Approaches that rely on proxies have the
potential advantage of simplicity, but require evidence
supporting their capacity to predict quality problems [46].
In this study, we found no significant association between
price or platform and the prevalence of calculation errors.
Further work is needed to explore whether other aspects
of content, design, or usability can provide a reliable way
for users to anticipate potential quality problems.
For healthcare professionals, there should be substantial
caution in actively recommending calculator apps without
thorough testing. Clinicians should consider asking about
app use as part of routine diabetic review and specifically
mention the potential risks associated with calculators
when teaching carbohydrate counting, taking the oppor-
tunity to promote trusted resources such as dedicated
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approaches, it is unlikely that common sense advice about
choosing heath apps would be actively harmful, and clini-
cians should take advantage of opportunities to promote
simple strategies, such as preferentially choosing apps
from known, reputable providers until CE-marked or US
Food and Drug Administration (FDA)-approved apps
become available and learning how to recognize these
quality marks. For patients who are unwilling to dis-
continue use of a calculator app, advice should focus
on the importance of double-checking data entry (to
address input issues) as well as establishing a ceiling in-
sulin dose above which any dose recommendations should
be ignored. If patients are willing, stepping through calcu-
lation may be helpful in exposing gross errors. However, it
is unlikely that informal testing, even if specifically di-
rected towards exposing the risk of overdose, for example,
by simulating implausible hyperglycemia, will uncover all
issues. Although the approach described in this study pro-
vides a template for robust review, the workload involved
should not be underestimated. App updates are frequent,
and require both evaluation of new features and confirm-
ation that existing functions still work. One app had intro-
duced an 11-screen configuration process to address the
complexity that had arisen as new features were added.
Alternative methods, such as expert peer review, may be
more efficient but require evidence to support their use in
favor of explicit, criterion-based assessment.
If it is infeasible for either patients or clinicians to sys-
tematically appraise the safety of health apps, it is also
unclear whether coordinated forms of quality assurance
will provide rapid redress. In the USA and Europe,
where regulatory guidance is now available [28,49], dose
calculators almost certainly meet the respective definitions
of a medical device and are therefore subject to oversight
[50]. However, none of the apps included in this study
appear to have completed registration, labeling, or other
general controls which are the minimal requirements for
products in both regimes. Most remained available in app
stores in October 2014, 12 months after the introduction
of FDA guidance. Regulators face an unenviable task of
balancing risk, regulatory burden and its consequential
impact on innovation, and the sheer volume of apps avail-
able [8,51,52]. However, allowing higher risk apps, such
as calculators, to escape even minimal oversight creates
a risk that harms go undetected because apps will escape
established mechanisms for surveillance. App accredit-
ation programs are a recent development, independent of
government regulators, with a specific focus on clinical
quality [48,53,54], but have yet to prove their ability to
provide robust assurance, at scale [55].
Previous literature has highlighted the potential for li-
ability and governance problems associated with tech-
nologies, such as telehealth, that transcend geographicboundaries [56]. Our findings suggest that apps based
on local medical practices may pose a risk when distrib-
uted in globalized app stores without regard to whether
the same practices operate in other markets. For insulin
dose calculation, the consequence of confusing ratio
adjustment factors is always overestimation of the re-
quired insulin dose. Apps from the USA assume a ratio
form that is inverse to that assumed by apps from some
European countries. The lack of universal standard ter-
minology, appropriate labeling, or a written formula in
most apps means that users have no way of discerning
the correct interpretation. It seems likely that this issue,
or variations of it, will apply to other kinds of medical
apps that are distributed in multiple locations. In Octo-
ber 2014 a diabetes tracking app integrated into Apple’s
own Health platform had to be modified after it was
discovered that measurements entered in SI units were
not being handled correctly [57]. To address localization
issues effectively, some form of coordination between reg-
ulators and public marketplaces, which control the distri-
bution of most apps, may be necessary.
The study also highlights the importance of develop-
ment context in understanding the risks that medical
apps may pose. App developers responding to enquiries
in this study frequently characterized their software as a
personal project, often responding to the need of a fam-
ily member or friend. We found no evidence of devel-
opers acting other than in good faith. However, such an
approach may be very different from a professional soft-
ware development context in which medical expertise
might be sought and formal quality engineering approaches
applied. Personal projects are unlikely to have the resources
available to pay for expert guidance, formal testing, or up-
dates as new evidence emerges. Consequently, unlike
traditional medical software, users and regulators can-
not assume that the app landscape is dominated, or
even substantially populated, by products produced by
medically competent developers. The findings emphasize
the value of due diligence to accompany testing of the
product itself when assessing the risk associated with
medical apps. When top-down regulation fails to provide
robust quality safeguards, consumer behavior and market
dynamics might help. The findings of this study provide
both clinicians and patients with enough evidence to en-
gage in open and informed exchanges about the appropri-
ateness of medical apps in the particular case of insulin
calculators, and future work will likely generate further in-
sights. This bottom-up approach, however, requires indi-
viduals to keep up with recent research in mHealth.
The strengths of this study include the exhaustive
approach used for sampling and the steps taken to
minimize bias and error during assessment. As a cross-
sectional analysis, however, the findings reflect issues
present at a particular point in time. Both the number of
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will change as apps are released, updated, and withdrawn.
Thus, specific findings may have changed, and clinical
users should perform their own assessment before recom-
mending, or discouraging users from, a particular app. Fu-
ture work should examine how issue prevalence changes
and whether new issues arise over time. Neither can this
study provide evidence of concrete harms resulting from
issues identified in the apps that were reviewed. Coordi-
nated programs of surveillance for harms resulting from
medical app use, whether run by regulators, accreditation
programs, or researchers, should be a priority.Conclusions
Despite potential benefits for patients, popular apps
offering insulin dose calculation carry a risk of incorrect
dose recommendations ranging from those that might
lead to suboptimal disease control to those with poten-
tially life-threatening consequences. Healthcare profes-
sionals should exercise caution in recommending higher
risk tools such as calculators without careful testing, rec-
ognizing that a technically accurate calculation is not the
same as one that is clinically safe. Given the volume of
apps now available, systemic issues affecting the safety and
suitability of medical apps may only be addressed satis-
factorily through coordinated action at national and inter-
national levels involving regulators, health agencies, and
app stores. This should seek to address the safety issues
that result from global medical app distribution including
the need to coordinate the collection of surveillance data
about possible harms, ensure that regulation is clear
and consistently enforced, and highlight the importance
of clinical expertise to developers of medical apps. Other-
wise, apps intended for use in chronic disease manage-
ment and other aspects of healthcare will continue to put
patients at avoidable risk of harm.Additional files
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